Stellar Biotechnologies, Inc. License Agreements
9 Contracts & Agreements
- First Amendment to Exclusive License Agreement, dated as of September 21, 2023, by and between Edesa Biotech Research, Inc. and Dr. Saul Yedgar (Filed With SEC on December 15, 2023)
- Third Amendment to Exclusive License Agreement, dated October 26, 2022, by and between the Registrant and Yissum Research Development Company (Filed With SEC on December 16, 2022)
- Exclusive License Agreement, dated as of March 16, 2021, by and between the Edesa Biotech Research, Inc. andDr. Saul Yedgar (Filed With SEC on March 22, 2021)
- License Agreement by and between Edesa Biotech Research, Inc. and NovImmune SA dated April 17, 2020 (Filed With SEC on April 23, 2020)
- License and Development Agreement, dated as of August 27, 2017, by and between the Registrant and Pendopharm, a division of Pharmascience Inc (Filed With SEC on August 30, 2019)
- Exclusive License Agreement, dated as of June 15, 2016, by and between the Registrant and Cipher Pharmaceuticals Inc (Filed With SEC on August 30, 2019)
- Second Amendment to Exclusive License Agreement, dated May 7, 2017, by and between the Registrant and Yissum Research Development Company (Filed With SEC on August 30, 2019)
- First Amendment to Exclusive License Agreement, dated April 3, 2017, by and between the Registrant and Yissum Research Development Company (Filed With SEC on August 30, 2019)
- Exclusive License Agreement, dated as of June 29, 2016, by and between the Registrant and Yissum Research Development Company (Filed With SEC on August 30, 2019)
